Cargando…

The Development and Clinical Applications of Oral Arsenic Trioxide for Acute Promyelocytic Leukaemia and Other Diseases

Appreciation of the properties of arsenic trioxide (ATO) has redefined the treatment landscape for acute promyelocytic leukaemia (APL) and offers promise as a treatment for numerous other diseases. The benefits of ATO in patients with APL is related to its ability to counteract the effects of PML::R...

Descripción completa

Detalles Bibliográficos
Autores principales: Chin, Lynn, Kumana, Cyrus R., Kwong, Yok-Lam, Gill, Harinder
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504237/
https://www.ncbi.nlm.nih.gov/pubmed/36145693
http://dx.doi.org/10.3390/pharmaceutics14091945
_version_ 1784796165487722496
author Chin, Lynn
Kumana, Cyrus R.
Kwong, Yok-Lam
Gill, Harinder
author_facet Chin, Lynn
Kumana, Cyrus R.
Kwong, Yok-Lam
Gill, Harinder
author_sort Chin, Lynn
collection PubMed
description Appreciation of the properties of arsenic trioxide (ATO) has redefined the treatment landscape for acute promyelocytic leukaemia (APL) and offers promise as a treatment for numerous other diseases. The benefits of ATO in patients with APL is related to its ability to counteract the effects of PML::RARA, an oncoprotein that is invariably detected in the blood or bone marrow of affected individuals. The PML::RARA oncoprotein is degraded specifically by binding to ATO. Thus ATO, in combination with all-trans retinoic acid, has become the curative treatment for ATO. The multiple mechanisms of action of ATO has also paved the way for application in various condition encompassing autoimmune or inflammatory disorders, solid organ tumours, lymphomas and other subtypes of AML. The development of oral formulation of ATO (oral ATO) has reduced costs of treatment and improved treatment convenience allowing widespread applicability. In this review, we discuss the mechanisms of action of ATO, the development of oral ATO, and the applications of oral ATO in APL and other diseases.
format Online
Article
Text
id pubmed-9504237
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95042372022-09-24 The Development and Clinical Applications of Oral Arsenic Trioxide for Acute Promyelocytic Leukaemia and Other Diseases Chin, Lynn Kumana, Cyrus R. Kwong, Yok-Lam Gill, Harinder Pharmaceutics Review Appreciation of the properties of arsenic trioxide (ATO) has redefined the treatment landscape for acute promyelocytic leukaemia (APL) and offers promise as a treatment for numerous other diseases. The benefits of ATO in patients with APL is related to its ability to counteract the effects of PML::RARA, an oncoprotein that is invariably detected in the blood or bone marrow of affected individuals. The PML::RARA oncoprotein is degraded specifically by binding to ATO. Thus ATO, in combination with all-trans retinoic acid, has become the curative treatment for ATO. The multiple mechanisms of action of ATO has also paved the way for application in various condition encompassing autoimmune or inflammatory disorders, solid organ tumours, lymphomas and other subtypes of AML. The development of oral formulation of ATO (oral ATO) has reduced costs of treatment and improved treatment convenience allowing widespread applicability. In this review, we discuss the mechanisms of action of ATO, the development of oral ATO, and the applications of oral ATO in APL and other diseases. MDPI 2022-09-14 /pmc/articles/PMC9504237/ /pubmed/36145693 http://dx.doi.org/10.3390/pharmaceutics14091945 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Chin, Lynn
Kumana, Cyrus R.
Kwong, Yok-Lam
Gill, Harinder
The Development and Clinical Applications of Oral Arsenic Trioxide for Acute Promyelocytic Leukaemia and Other Diseases
title The Development and Clinical Applications of Oral Arsenic Trioxide for Acute Promyelocytic Leukaemia and Other Diseases
title_full The Development and Clinical Applications of Oral Arsenic Trioxide for Acute Promyelocytic Leukaemia and Other Diseases
title_fullStr The Development and Clinical Applications of Oral Arsenic Trioxide for Acute Promyelocytic Leukaemia and Other Diseases
title_full_unstemmed The Development and Clinical Applications of Oral Arsenic Trioxide for Acute Promyelocytic Leukaemia and Other Diseases
title_short The Development and Clinical Applications of Oral Arsenic Trioxide for Acute Promyelocytic Leukaemia and Other Diseases
title_sort development and clinical applications of oral arsenic trioxide for acute promyelocytic leukaemia and other diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504237/
https://www.ncbi.nlm.nih.gov/pubmed/36145693
http://dx.doi.org/10.3390/pharmaceutics14091945
work_keys_str_mv AT chinlynn thedevelopmentandclinicalapplicationsoforalarsenictrioxideforacutepromyelocyticleukaemiaandotherdiseases
AT kumanacyrusr thedevelopmentandclinicalapplicationsoforalarsenictrioxideforacutepromyelocyticleukaemiaandotherdiseases
AT kwongyoklam thedevelopmentandclinicalapplicationsoforalarsenictrioxideforacutepromyelocyticleukaemiaandotherdiseases
AT gillharinder thedevelopmentandclinicalapplicationsoforalarsenictrioxideforacutepromyelocyticleukaemiaandotherdiseases
AT chinlynn developmentandclinicalapplicationsoforalarsenictrioxideforacutepromyelocyticleukaemiaandotherdiseases
AT kumanacyrusr developmentandclinicalapplicationsoforalarsenictrioxideforacutepromyelocyticleukaemiaandotherdiseases
AT kwongyoklam developmentandclinicalapplicationsoforalarsenictrioxideforacutepromyelocyticleukaemiaandotherdiseases
AT gillharinder developmentandclinicalapplicationsoforalarsenictrioxideforacutepromyelocyticleukaemiaandotherdiseases